Eton Pharmaceutical ETON 深 滬
已收盤 10-03 16:00:00 美东时间
19.93
+0.130
+0.66%
華盛通- 最 高20.275
- 今 開19.80
- 成交量 26.97万股
- 最 低 19.50
- 昨 收 19.80
- 總市值 5.34亿
- 52周最高 23.00
- 市盈率 靜 --
- 換手率 1.01%
- 52周最低 7.58
- 委 比 90.60%
- 總股本 2681.75万
- 歷史最高 23.00
- 量 比 0.57
- 振 幅 3.91%
- 歷史最低 1.95
- 每 手 1
- 風險率 3.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Soligenix Expands European MAB To Provide Addl Medical/Clinical Strategic Guidance As It Advances Confirmatory Phase 3 Placebo-Controlled Study Evaluating Safety And Efficacy Of HyBryte In CTCL Treatment
In preparation for health authority interactions in pursuit of marketing approvals in Europe PRINCETON, N.J., Sept. 30, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a
09-30 19:36
Soligenix Announces Pricing of $7.5 Million Public Offering
PRINCETON, N.J., Sept. 26, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializin...
09-26 18:33
PDS Biotech Reports 29.5-Month Median Overall Survival In Phase 2 Trial For Advanced Head And Neck Cancer; Says Encouraging Efficacy Signal Observed In Difficult To Treat Category Of Advanced Head And Neck Cancer Patients
First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients with CPS
09-18 20:47
CytoSorbents Provides DrugSorb-ATR Regulatory Update
PRINCETON, N.J., Sept. 16, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surge...
09-16 19:00
Miami International Holdings Launches Next-Generation Options Trading Floor in Miami
MIAMI and PRINCETON, N.J., Sept. 16, 2025 /PRNewswire/ -- Miami International Holdings, Inc. (MIAX®) (NYSE: MIAX), a technology-driven leader in building and operating regulated financial ma...
09-16 18:45
BioNTech, Bristol Myers Squibb Present Interim Data From Global Randomized Phase 2 Trial Evaluating Pumitamig, Investigational Bispecific Antibody Targeting PD-L1 X VEGF-A, Plus Chemotherapy In ES-SCLC Patients
PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer ("ES-SCLC"), expanding evidence for
09-08 23:03
Miami International Holdings Reports Trading Results for August 2025
PRINCETON, N.J. and MIAMI, Sept. 8, 2025 /PRNewswire/ -- Miami International Holdings, Inc. (NYSE: MIAX) (MIAX), a technology-driven leader in building and operating regulated financial mark...
09-08 21:15
CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference
PRINCETON, N.J., Sept. 5, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surger...
09-05 19:00
PDS Biotechnology Reports Median Overall Survival Of 39.3 Months In HPV16-Positive Head And Neck Cancer Patients
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months*VERSATILE-003 Phase 3 trial in
08-25 20:34
CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR
FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization PRINCETON, N.J., Aug. 20, 20...
08-20 19:00
